在固体器官移植接收者中,在基于Omicron的顺序接种疫苗后,XBB亚系中和的快速消失和恢复
Trevor S Johnston1, Camille Hage1, Aura T Abedon2
1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
概括
像XBB.1.5这样的Omicron变异的中和性在移植接受者中双价增强剂后3个月后减弱. 第二个增强剂可以改善中和,这表明需要定期增强以保持保护.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 移植科学 移植科学
背景情况:
- 固体器官移植接受者 (SOTRs) 已经改变了免疫反应.
- 在SOTR中,对含有Omicron的助推剂的保护的持久性尚不清楚.
研究的目的:
- 在SOTRs中研究双价COVID-19增强疫苗接种后对Omicron变异的中和的持久性.
- 评估第二剂强剂对中和耐久性的影响.
主要方法:
- 该研究评估了对Omicron XBB.1.5变种的中和.
- 抗体中和被测量在不同的时间点后,增强剂量.
- 考虑了混合免疫力 (先前感染加上接种疫苗) 的影响.
主要成果:
- 在第一个双价增剂后的3个月内,XBB.1.5的中和显著减弱.
- 第二次增强剂量改善了中和的峰值和持续时间.
- 混合免疫增强了中和的规模和寿命.
结论:
- 需要定期进行补充疫苗接种,可能每3至6个月一次,以保持SOTRs对Omicron变种的充分中和.
- 双相增强剂提供了暂时的保护,突出显示了在这个脆弱人群中持续免疫接种的需要.
更多相关视频
08:17A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
14.3K
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
17.2K
相关概念视频
00:42Cross-reactivity
31.0K
Overview
31.0K
02:45Blood Transfusion and Agglutination
10.8K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.8K
01:40Cell-mediated Immune Responses
68.1K
Overview
68.1K